Literature DB >> 505346

Imaging sites of airway obstruction and measuring functional responses to bronchodilator treatment in asthma.

S K Chopra, G V Taplin, D P Tashkin, E Trevor, D Elam.   

Abstract

The sites of airway obstruction and dilatation after terbutaline administration were studied by inhalation imaging and pulmonary function tests in 12 stable asthmatic patients. Inhaled terbutaline as a therapeutic aerosol decreased airway resistance (Raw) and improved radioaerosol (Ae) images in nine, delta V max50 in three, and xenon (Xe) images in five of 12 subjects, suggesting that its predominant site of action was on major airways. Subcutaneously injected terbutaline improved Raw, delta V max50, and Ae images in 11 and Xe images in eight subjects indicating that it released bronchospasm in the major and minor airways. These findings in asthma suggest that aerosol and Xe imaging procedures are sensitive indicators of large and small airway obstruction respectively.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 505346      PMCID: PMC471103          DOI: 10.1136/thx.34.4.493

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  14 in total

1.  A rapid plethysmographic method for measuring thoracic gas volume: a comparison with a nitrogen washout method for measuring functional residual capacity in normal subjects.

Authors:  A B DUBOIS; S Y BOTELHO; G N BEDELL; R MARSHALL; J H COMROE
Journal:  J Clin Invest       Date:  1956-03       Impact factor: 14.808

2.  The influence of clinical factors on site of airway obstruction in asthma.

Authors:  R Antic; P T Macklem
Journal:  Am Rev Respir Dis       Date:  1976-11

3.  Volume of isoflow. A new test in detection of mild abnormalities of lung mechanics.

Authors:  M Hutcheon; P Griffin; H Levison; N Zamel
Journal:  Am Rev Respir Dis       Date:  1974-10

4.  Bronchial deposition and clearance of aerosols.

Authors:  R E Albert; M Lippmann; H T Peterson; J Berger; K Sanborn; D Bohning
Journal:  Arch Intern Med       Date:  1973-01

5.  Site of airway obstruction in asthma as determined by measuring maximal expiratory flow breathing air and a helium-oxygen mixture.

Authors:  P J Despas; M Leroux; P T Macklem
Journal:  J Clin Invest       Date:  1972-12       Impact factor: 14.808

Review 6.  Lung defense mechanisms (first of two parts).

Authors:  M Newhouse; J Sanchis; J Bienenstock
Journal:  N Engl J Med       Date:  1976-10-28       Impact factor: 91.245

7.  Improved radioaerosol administration system for routine inhalation lung imaging.

Authors:  M Hayes; G V Taplin; S K Chopra; D E Knox; D Elam
Journal:  Radiology       Date:  1979-04       Impact factor: 11.105

8.  Imaging experimental pulmonary ischemic lesions after inhalation of a diffusible radioaerosol: concise communication.

Authors:  G V Taplin; S K Chopra; D Elam
Journal:  J Nucl Med       Date:  1977-03       Impact factor: 10.057

9.  Early detection of chronic obstructive pulmonary disease using radionuclide lung-imaging procedures.

Authors:  G V Taplin; D P Tashkin; S K Chopra; O E Anselmi; D Elam; B Calvarese; A Coulson; R Detels; S N Rokaw
Journal:  Chest       Date:  1977-05       Impact factor: 9.410

10.  A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease.

Authors:  A B DUBOIS; S Y BOTELHO; J H COMROE
Journal:  J Clin Invest       Date:  1956-03       Impact factor: 14.808

View more
  3 in total

Review 1.  Ventilation.

Authors:  G M Sterling
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

2.  Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream").

Authors:  D M Newnham; B J Lipworth
Journal:  Thorax       Date:  1994-08       Impact factor: 9.139

3.  Moment analysis of the flow-time curve after breathing gases of different densities.

Authors:  M R Partridge; A C Watson; K B Saunders
Journal:  Thorax       Date:  1981-01       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.